Breaking News

Fujifilm to Invest $90M in Bio CDMO Biz

Increasing its biopharma production capacity and capabilities to meet customer demand

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Corporation announced plans to invest approximately $90 million to expand its bio contract development and manufacturing organization (CDMO) business— Fujifilm Diosynth Biotechnologies (FDB). This investment will include the expansion of existing production facilities at its North Carolina location to support the growing needs of its customer portfolio. Additional investments are planned at the company’s other locations; details will be announced in the first quarter of 2019.   Fujifi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters